49 results about "Streptococcus pneumoniae Infections" patented technology

Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human. In a particular embodiment, the present invention provides an isolated, recombinant or synthetic S. pneumoniae Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386) as a disease related antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or for use in the treatment of an S. pnewnoniae infection in a human. It further provides antibodies that specifically bind to the S. pneumoniae disease related antigens identified herein for use in the treatment of a an S. pneumoniae infection in a human, such as for example in a treatment to induce immunological memory in a human against S. pneumoniae, i.e. in a vaccination treatment of S. pneumoniae. It is also an aspect of the present invention to provide the use of any one of the S. pneumoniae disease related antigens as identified herein, or of the antibodies specific for said antigens in methods to diagnose for a S. pneumoniae disorder in a human.

The present invention is primarily directed to a method for preventing infection of a mammalian subject with S. pneumoniae, wherein said method comprises administering to said subject an effective amount of one or more S. pneumoniae cell wall and / or cell membrane proteins and / or immunogenically-active fragments, derivatives or modifications thereof, wherein said proteins are selected from a defined group of immunogenic proteins. The present invention further provides vaccine compositions containing said cell wall and / or cell membrane proteins.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The present invention provides conjugates of pan DR binding peptides with Streptococcus pneumoniae polysaccharides, and methods of preventing and treating diseases associated with Streptococcus pneumoniae infection with such conjugates.

Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and / or cell membrane proteins and / or immunogenically-active fragments, derivatives or modifications thereof, wherein said proteins are selected from a defined group of proteins associated with age-dependent immunological responses.

The present invention belongs to the field of chemically synthesized medicine and its preparation process. The medicine of the present invention is synthesized with amantadine, moroxydine, 5-Fu (5-Fc), isoniazid and other clinical medicine and polyoxometallate, and through self-assembling. The said polyoxometallate includes heteropoly acid salts of Keggin type with chemical expression XM12O40n-, Dowson type X2M18O62n- and of chemical expression LnW10O36n-. The combined use of said medicines and polyoxometallate has obvious curative effect on intractable streptococcus pneumoniae infection.

The invention provides glycoconjugate, a specific preparation method for preparing the glycoconjugate in the mode that primary hydroxyl of bacterial capsular polysaccharide is oxidized into an aldehyde group to react with primary amino of carrier protein lysine, and an immunogenicity composition containing the glycoconjugate. The invention further discloses application of the glycoconjugate and the immunogenicity composition to preparation of drugs or vaccines for preventing and / or treating individual streptococcus pneumonia infection and diseases related to streptococcus pneumonia. The glycoconjugate has the characteristics of higher immunogenicity and higher bactericidal effect.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

The invention relates to a streptococcus-pneumoniae-toxicity-reducing live vaccine used for preventing streptococcus-pneumoniae infection. The vaccine is the composition of streptococcus pneumoniae strains which contain streptococcus pneumoniae SPD-1672 and have gene function deficiency, can effectively prevent the streptococcus-pneumoniae infection, has strong safety and good protection effect, and is easy for large-scale production and potential for generalization.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention relates to application of verbascoside in preparation of a pneumonia treatment drug. The treatment effect of the verbascoside to streptococcus pneumoniae infection is proved through sheep red blood cell hemolysis test, protection experiment of the human pulmonary epithelial cell (A549) damage and a mouse streptococcus pneumoniae pneumonia pneumonia model. Compared with antibiotic treatment, when the verbascoside is used for treatment, so that the pneumonia treatment drug has the advantages that no drug resistance exists and the curing rate is high.

The invention relates to the fields of genetic engineering technology and diagnostic reagents and provides a chemosynthetic extracellular region gene fragment of streptococcus pneumonia PspA protein and expression and application thereof. According to the invention, strong epitope in streptococcus pneumonia PspA protein is screened through computer analysis, the fragment consisting of the 33rd amino acid to the 109th amino acid, altogether 77 amino acids, is used, codon preferred by prokaryotes is selected, and a brand new gene sequence of the epitope is chemically synthesized; and through usage of genetic engineering technology, the gene fragment is expressed, and the fragment of the strong epitope in streptococcus pneumonia PspA protein is prepared. The expressed protein can be used for research and development of vaccines, detection of streptococcus pneumonia infection antibodies and preparation of monoclonal antibodies and polyclonal antibodies.

Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INVl 04B)) identified in Streptococcus pneumoniae isolate INVl 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141 that are absent from Streptococcus pneumoniae isolate INV104. The polypeptides, including fragments and variants thereof, may be used in immunogenic compositions for prophylactic or therapeutic immunization against Streptococcus pneumoniae. The polypeptides are also disclosed to be used in compositions useful for the production of antibodies and immunostimulants. Also presented are methods of inhibiting Streptococcus pneumoniae, methods of treating Streptococcus pneumoniae infection, methods of identifying inhibitors of Streptococcus pneumoniae and methods for diagnosing / detecting Streptococcus pneumoniae infection.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimens that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Provide is a novel prophylactic and / or therapeutic agent for Streptococcus pneumoniae infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and / or treat Streptococcus pneumoniae infection. The prophylactic and / or therapeutic agent for Streptococcus pneumoniae infection, comprises a bacterium belonging to the genus Enterococcus. Also provided are: a medicine for prevention and / or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus; and a food for prevention and / or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus.

The invention discloses a medicament for treating streptococcus pneumonia infected pneumonia and a preparation method thereof. The medicament is prepared from the following raw medicinal materials: straight ladybell, pericarp of bretschneider pear, mongolian snakegourd root, root of lobed kudzuvine, fritillaria, fragrant solomonseal rhizome, rhizome of Chinese tupistra, edible manna lichen, rhizome of giantreed, herb of marestail, herb of little platanthera, raw milkvetch root, codonopsis pilosula, inner shell membrane of fowl's egg, herb of wight parnassia, licorice root, frost mulberry leaves, platycodon root, herb of common peganum, peucedanum medicum dunn, herb of threeflower bluebeard, herb of fourangled circaea, dried rehmannia root, japonica rice, filliform cassytha herb, all-grass of intermediate peashrub, herb of ceylon leucas, root of siebold primrose, rhizome or herb of purple bergenia, fermented soybean, white hyacinth bean, divaricate saposhnikovia root, fresh ginger and citrus aurantium. The medicament disclosed by the invention has the following beneficial effects: the medicament has the effects of clearing heat to moisten the lung, nourishing yin, promoting the secretion of saliva, supplementing qi, tonifying the lung and dispelling wind to dredge collaterals, and is mainly used for treating dryness evil lung-injuring type streptococcus pneumonia infected pneumonia; and the medicament is simple and convenient in preparation process, small in toxic or side effects, convenient in administration, easy to manufacture and low in cost, can directly reach a focus, is short in curative time, and can avoid relapse after curing.

The invention relates to application of amentoflavone in research and development of medicines for treating pneumonia. Rabbit erythrocyte haemolysis tests, human pulmonary epithelial cell (A549) injury protection tests and a mouse streptococcus pneumonia model prove that the amentoflavone has a treatment effect on infection of streptococcus pneumonia. Compared with treatment with antibiotics, the amentoflavone for treatment has the characteristics of no drug resistance and high protection performance.

A method of preventing and / or treating S. pneumoniae infection in mammalian subjects, wherein said method comprises administering to said subjects a composition comprising one or more agents that are capable of inhibiting the binding of the S. pneumoniae cell wall protein FBA to the respiratory tract cells of said subject.

Provided is a multivalent pneumococcal conjugate composition comprising 22 to 27 different pneumococcal capsular polysaccharide-protein conjugates wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of Streptococcus pneumoniae, wherein the Streptococcus pneumoniae serotype is selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B. Also provided are methods of producing the multivalent pneumococcal conjugate compositions and methods of using the multivalent pneumococcal conjugate compositions to prevent a Streptococcus pneumoniae infection or disease in a subject. Also provided are immunogenic compositions comprising at least one polysaccharide-protein conjugate, wherein the polysaccharide is a capsular polysaccharide from Streptococcus pneumoniae serotypes 15A, 15C, 23A, 23B, 24F and / or 35B; and methods of making the immunogenic compositions.

The invention discloses a pneumolysin (Ply) mutant and an application thereof as a mucosal immunoadjuvant. A gene of the mutant comprises deltaPly with nucleotide sequence of SEQ ID NO.2. The Ply mutant (deltaPly) is used as the mucosal immunoadjuvant to prepare streptococcus pneumoniae fusion protein vaccines to prevent streptococcus pneumoniae infection immunity and is safe and effective.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention relates to an antiviral traditional Chinese medicine composition for a respiratory system. The traditional Chinese medicine composition, namely an anti-inflammatory and antipyretic mixture, has a remarkable treatment effect on respiratory system infectious mouse models induced by influenza viruses, streptococcus pneumoniae and beta hemolytic streptococcus, has the effect equivalent to that of oseltamivir and amoxicillin under the clinical use dosage, and also provides a new thought for clinical treatment of novel coronavirus pneumonia. The invention adopts the technical scheme that the anti-inflammatory and antipyretic mixture is used for treating influenza virus H1N1 / FM1 strain infection, streptococcus pneumoniae infection and beta hemolytic streptococcus infection. The dosage of the anti-inflammatory and antipyretic mixture is 20mL / kg, 10mL / kg or 5mL / kg.

The invention relates to an ultra-fast real-time nucleic acid detection method for Streptococcus pneumoniae. According to the ultra-fast real-time nucleic acid detection method, nucleic acid is extract, amplification is performed with fluorescent labeled primers in a special buffer solution in a disk-type reaction container under the catalysis of an enzyme, and the nucleic acid template content ina sample is real-timely and quantitatively detected, wherein the reaction time is substantially shortened compared to the previous fluorescence quantitative nucleic acid detection method through thespecial buffer solution and the disk-type reaction container, and is shortened to 5-10 min from the original time of more than 1 h, such that the rapid detection of Streptococcus pneumoniae infectionis truly achieved. According to the present invention, the ultra-fast real-time nucleic acid detection method has advantages of short reaction time, simple operation, high specificity and high promotion value, and is suitable for the detection of sudden acute Streptococcus pneumoniae infection.